secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001808805-23-000066
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q2 net loss $15.8M; cash runway extended through 2025-2026
-------------------------------------------------------------------

- Operating expenses $19.0M, up 23% YoY from $15.5M driven by product development headcount.
- Net loss $15.8M vs $14.7M in Q2 2022; company pre-revenue, still in development stage.
- Cash, equivalents, and investments $286.7M as of June 30, 2023; CEO says funds operations into 2026.
- CEO reports progress integrating sample prep, probes, chips, instrument, and software for commercial launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000066/0001808805-23-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880523000066/naut-20230802.htm
  HTML page:      https://secwatch.observer/filing/0001808805-23-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer